Columbus-based clinical research company collaborates with super network to advance the efficiency of its clinical trials and expand expertise across vaccine, internal medicine, dermatology, and many additional therapeutic areas.

COLUMBUS, OH, March 24, 2021 /24-7PressRelease/ — Aventiv Research, a leading independent, multi-therapeutic inpatient and outpatient clinical research center, announced its strategic alliance with hyperCORE International, a multi-national Integrated Research Organization. Formed in 2019, the IRO is a super network of highly experienced and awarded clinical research companies. It is an industry leader, providing Phase I-IV clinical trial services with more than 90 active research sites across North and South America and is the second-largest clinical research site organization globally. With the inclusion of Aventiv Research, its 11 member companies have completed more than 7000 clinical studies.

Through a highly competitive, invite-only, rigorous audit process, Aventiv Research met the IRO’s inclusionary criteria and was granted membership. “We are grateful to be a part of this well-respected and elite ecosystem where we can work together to enhance lives and improve the future of medicine,” said Dr. Samir Arora, President and Medical Director of Aventiv Research. “This partnership is an ideal fit for our growth goals and aligns with our core values.”

Aventiv Research will leverage the IRO’s established business development infrastructure to expand its access to a significantly wider array of studies not available to the company before. “Aventiv is a great match for the partnership as our trend-focused and specialty-based approach is right in line with the hyperCORE model,” commented Rachel Flora, Business Development Manager of Aventiv Research. “The other sites in the network are very similar to ours as they are of comprised strong, multispecialty sites.”

The location of Aventiv Research and its diverse patient database were key factors to ensure the IRO’s presence in Ohio. “Aventiv adds to hyperCORE’s diversity and geographic footprint so that it has an even better ability to perform in precisely the way our industry demands,” added Dr. Jeff Kingsley, CEO of IACT Health and COO of hyperCORE International. “They are a wonderful addition to our super network aimed at serving the industry and our patients in an unparalleled fashion. I am proud to welcome them.”

hyperCORE International is committed to the highest standard of research excellence with subject safety, data integrity, rapid study startup, competitive enrollment, and outstanding subject retention as top priorities. Its members have won numerous awards for performance, quality, and innovation.

For more information about Aventiv Research, visit https://www.aventivresearch.com/.

About Aventiv Research

Aventiv Research exists to make novel medicines accessible to its patients and deliver industry-best pharmaceutical data to its sponsors. Its mission is to enrich the lives of both its team members and patients by putting medical research to work. Currently operating in two states with four independent research sites, Aventiv specializes in phase I-IV pharmaceutical, device, and diagnostic clinical trials in a variety of therapeutic areas. Built on the core values of dedication, integrity, resourcefulness, and professionalism, the company embraces a visionary, entrepreneurial spirit that compels its ambassadors to blaze new trails with proprietary systems and processes.

Founded in 2007 by Dr. Samir Arora, a proven leader with more than 15 years of clinical research experience, Aventiv Research has conducted over 450 clinical trials with more than 55 pharmaceutical sponsors and has helped 16 drugs to become approved by the FDA and available for use.

Find out more at www.aventivresearch.com, Facebook, and Instagram.

About hyperCORE International

Formed in 2019, hyperCORE International is a super network of highly experienced and awarded clinical research site/network companies. It is an industry leader, providing Phase I-IV clinical trial services with more than 90 active research sites across the globe. Its member companies have more than 100 years of combined experience and completed more than 7,000 studies helping to evaluate thousands of new drugs and treatments in more than 140,000 patients. Each member operates as an independent company but integrates common functions to streamline business and clinical operations through harmonization and sharing of best practices.

hyperCORE International is committed to the highest standard of research excellence with subject safety, data integrity, rapid study startup, competitive enrollment, and outstanding subject retention as top priorities. Its members have won numerous awards for performance, quality, and innovation.

Learn more at http://www.hyperCOREinternational.com.

—
For the original version of this press release, please visit 24-7PressRelease.com here